Enanta Pharmaceuticals | ENTA - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
AbbVie USD 5.57B 2.9B 2026-03
Amgen USD 1.51B 2.41B 2025-12
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Biogen USD 377.7M 433.7M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Halozyme Therapeutics USD 180.33M 281.18M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Immunic USD -19.3M 6.28M 2025-12
Incyte USD 343.6M 46.34M 2026-03
Insmed USD -162.1M 164.84M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
J&J USD 8.66B 839M 2026-06
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
Ligand Pharmaceuticals USD 56.78M 84.36M 2025-12
Merck USD 3.42B 3.32B 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 3.84B 802M 2026-03
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD 5.18B 6.82B 2026-03
PTC Therapeutics USD -2.46M 136.62M 2026-03
Roche Holding CHF 11.17B 6.38B 2026-06
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03